The Real-World Data in Japanese Patients with Unresectable Hepatocellular Carcinoma Treated with Lenvatinib from a Nationwide Multicenter Study.
Kaoru TsuchiyaMasayuki KurosakiAzusa SakamotoHiroyuki MarusawaYuji KojimaChitomi HasebeHirotaka AraiKouji JokoMasahiko KondoKeiji TsujiTetsuro SohdaHiroyuki KimuraChikara OgawaYasushi UchidaShuichi WadaHaruhiko KobashiKoichiro FurutaMasaya ShigenoAtsunori KusakabeTakehiro AkahaneRyoichi NaritaHideo YoshidaAkeri MitsudaYasushi IdeTomomichi MatsushitaNamiki Izuminull On Behalf Of Japanese Red Cross Liver Study GroupPublished in: Cancers (2021)
LEN showed a high response rate in real-world practice. Pretreatment factors, including ALBI score, AFP, and major vascular invasion are important in making a treatment strategy for patients with u-HCC. The patients with bone metastasis would be candidates for new therapeutic approaches.